Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders

Background: Thrombosis is the most important cardiovascular complication of classical myeloproliferative disorders (MPDs). Endothelial dysfunction (ED) is known to play a major role in the mechanism of thrombophilia in MPDs. Methods: Endothelial dysfunction and its associations with other parameters were investigated. A total of 18 patients with polycythemia vera (PV), 24 with essential thrombocytosis (ET), 7 with primary myelofibrosis (PMF), and 30 healthy patients as a control group were included in the study. To assess the ED, flow-mediated dilatation (FMD) measurements were used. Results: The FMD (%) result showing ED was determined as 9.9 (0.0-21.6) in the patients with PV, 7.3 (0.0-30.5) in patients with ET, 7.5 (0.0-18.0) in patients with PMF, and 13.9 (6.2-26.7) in the control group. The FMD (%) was markedly impaired in all patients with MPD compared to the control patients (7.8 [0.0-30.5] vs 13.9 [6.15-26.8], P = .02). According to the disease subtypes, FMD (%) was significantly lower in the ET group than in the control group (P = .01). Conclusion: Endothelial function was assessed in patients with MPD having FMD and was determined to demonstrate ED. Lower FMD was associated with older age, leukocytosis, thrombocytosis, and thrombosis history.

• Publication year

  2018

• Venue

  Clinical and applied thrombosis/hemostasis

• Publication date

  2018-04-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1076029618766260PMID 29683036PMCID 6714746
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aging and hypertension decrease endothelial NO‐related dilating function and gamma‐glutamyl transferase activity but not S‐nitrosoglutathione‐induced aortic vasodilation

  2018cited by this paper
• The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels.

  2017cited by this paper
• L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia.

  2017cited by this paper
• The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

  2016cited by this paper
• In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.

  2014cited by this paper
• Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation

  2013influential reference
• Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

  2013cited by this paper
• Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management

  2012cited by this paper
• Thrombotic disease in the myeloproliferative neoplasms.

  2012influential reference
• Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.

  2011cited by this paper
• Assessment of flow-mediated dilation in humans: a methodological and physiological guideline.

  2011cited by this paper
• Polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management

  2011influential reference
• Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

  2011influential reference
• Thrombosis in primary myelofibrosis: incidence and risk factors.

  2009cited by this paper
• Soluble CD40 ligand and endothelial dysfunction in aspirin‐treated polycythaemia vera patients

  2009cited by this paper
• Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

  2009cited by this paper
• Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms–biologically plausible but clinically uncertain

  2009cited by this paper
• Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

  2008cited by this paper
• Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients.

  2008cited by this paper
• Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.

  2007cited by this paper
• Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.

  2007cited by this paper
• Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.

  2006cited by this paper
• Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.

  2005cited by this paper
• Detection of endothelial dysfunction with brachial artery ultrasound scanning.

  2003cited by this paper
• Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders

  2002cited by this paper
• The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia

  2001cited by this paper
• Polycythemia Vera and Essential Thrombocythemia

  2001cited by this paper
• Endothelial dysfunction in patients with polycythaemia vera

  2001influential reference
• Cardiovascular Manifestations of Myeloproliferative Disorders: A Review of the Literature.

  1999cited by this paper
• Markers of Endothelial and Platelet Status in Patients with Essential Thrombocythemia and Polycythemia Vera.

  1999cited by this paper
• Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients

  1999cited by this paper
• Increased levels of the soluble adhesion molecule E-selectin in patients with chronic myeloproliferative disorders and thromboembolic complications.

  1998cited by this paper
• CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

  1998cited by this paper
• European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): A Randomized Trial

  1997cited by this paper
• Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment.

  1995cited by this paper
• Close relation of endothelial function in the human coronary and peripheral circulations.

  1995cited by this paper
• The hypercoagulability of polycythemia vera.

  1993cited by this paper
• Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.

  1992influential reference
• Clinical course of essential thrombocythemia in 147 cases

  1990cited by this paper
• In vitro platelet adhesion to vascular subendothelium: Studies in patients with polycythaemia vera

  1988cited by this paper
• Essential thrombocythemias. Clinical evolutionary and biological data

  1986cited by this paper
• [Essential thrombocythemias].

  1957cited by this paper

• Polycythemia vera as a cause of systemic hypertension.

  2026cites this paper
• Independent Relationship Between Uveitis and Increased Left Atrial Volume Index in Ankylosing Spondylitis Patients

  2024cites this paper
• Primary myelofibrosis with thrombophilia as first symptom combined with thalassemia and Gilbert syndrome: A case report

  2022cites this paper
• Endothelium state in Ph-negative myeloproliferative neoplasms

  2021cites this paper
• Covert Brain Infarcts in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders

  2021cites this paper
• COVID 19 disease independently predicted endothelial dysfunction measured by flow-mediated dilatation

  2021cites this paper
• Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis

  2021cites this paper
• Two Cases of Severe Hypertension in JAK2 Mutation-Positive Myeloproliferative Neoplasms

  2020cites this paper
• Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper

  2019cites this paper